The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The US hedge funds control this share, I'm sure they just short it every time it makes any rise.
Perhaps tomorrow, there's too many sellers right now.
Hopefully the market makers are setting things up for 110p tomorrow, the order book looks very strong.
David Norwood retired from 4D Pharma for anyone not aware, he has been selling his shares gradually.
It's consolidating nicely, unfortunately there were some people taking profits at 106 and 107p. Market maker seems very keen to get this to 110p.
In my opinion, we are at this level because US hedge funds have been shorting this stock until very recently.
https://shorttracker.co.uk/company/GB00BJL5BR07/
As you said, 4D set a target of Jan 2021. I'm hoping the May extension is just a formality for legal purposes, it doesn't make sense to me to delay the merger that long.
Correction, the short could still exist but it is small enough that they no longer need to disclose it.
Citadel have closed their short once again:
https://shorttracker.co.uk/company/GB00BJL5BR07/
@Novice20 In this video at the 7:00 mark:
https://www.youtube.com/watch?v=8ojyr5oQToY
Basically they were still having difficulty recruiting participants 2 months ago.
Just be careful guys, Citadel are shorting this stock again.
https://shorttracker.co.uk/company/GB00BJL5BR07/
The bot could decide to take us back down to 90p as it has done so many times before.
From the SITC website (times are American Eastern time):
"Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020."
Don't 4D have to release the RNS to the market beforehand? RNS at 12PM?
The shorters these days appear on new accounts, feign an interest in shares and then try to sow doubt. Any of these new accounts appear saying things like they love this share but have some doubts, just report them.
I've been rewatching Duncan's interview following the completion of the Part A MRx0518/Keytruda trial.
Video link: https://www.youtube.com/watch?v=gDJVJcIDZAM
Here's what I think is significant:
1. The patients on this trial have failed to respond to previous therapies. These are arguably the toughest people to treat and the response rate is 42% in this initial group of 12 people.
2. Some people in the trial have been taking 4D Pharma's drug twice daily for over a year, that's a huge potential cash flow.
3. Duncan has added new cancer types to the Part B study potentially allowing this drug to treat all cancers.
4. Duncan says MRx0518 works with other checkpoint inhibitors opening the door for many further collaborations to be made.
5. 4D are looking to get accelerated approval for this drug due to the unmet need for new therapies in refractory patients.
6. Data so far shows MRx0518 to have a very good safety profile.
I've also rewatched some of the presentation which was released prior to the completion of Part A.
Video link: https://vimeo.com/426041218
Here's what I think is significant:
1. For the cancers that the Part A study treated, there were approximately 144,000 people total diagnosed in the USA for 2019, a huge market.
2. As a monotherapy, MRx0518 has shown the ability to reduce tumour volume in mice.
3. Some of the people that failed to respond in the Part A trial left very early in the trial, maybe they were just too sick. I wonder what the success rate would be in cancer patients that are not as gravely ill.
4. Two people with partial responses didn't respond until over 16 weeks into the trial.
5. One person had a 74% tumour response and another had a 51% tumour response.
6. Before joining the trial, one person had 7 prior treatments (which at best kept her cancer stable) before getting a partial response on the MRx0518/Keytruda trial, at the time of the presentation she has been on the trial for around a year.
7. This same patient has a mutation that is thought to reduce the likelihood of checkpoint inhibitors from working.
Disclaimer: This is the information I gathered from these two videos, it may contains errors or inaccuracies. Do your own research and know the risks. I am not giving you any investment advice.
Good read trendz, might want to recheck that last claim that £7.61 is an 850% upside, nowhere near by my calculations.
Has the shareholder merger vote already taken place or does anyone know when to expect it?
Anyone with L2 look at how much the autotrader is buying in the last 10 minutes of trading.
https://twitter.com/4dpharmaplc/status/1324713748788117507
"4D pharma believes that oncology is probably where live biotherapeutics will make their first significant impact. Earlier this year, 4D pharma produced the world’s first positive clinical data for a live biotherapeutic in oncology, and in a particularly difficult, highly refractory patient population where other therapies have been ineffective."
Here's my understanding of the news due next week but please do your own research and know the risks.
1. Update from MRx0518 monotherapy prior to surgical tumour removal study. There is already some data on monotherapy data with mice at the following link so we'll hopefully see how the effects translate to human patients:
https://www.4dpharmaplc.com/download_file/force/276/311
2. Update on part A of Keytruda/MRx0518 combination study of 12 people. We have already received the excellent results in August 2020 but we should hopefully find out how many of the patients are still receiving the treatment. The aim of these drugs is control the cancer long-term.
Here is a video explaining early results of the part A therapy:
https://vimeo.com/426041218
Here is the RNS for the completed part A study:
https://www.lse.co.uk/rns/DDDD/mrx0158-keytruda-part-a-clinical-benefit-data-drn4var8cdoty27.html
3. Update on part B of the Keytruda/MRx0518 combination study, the treatment is being expanded to perhaps 5 times more people. Part A showed a clinical response in 42% of people so we'll hope to see indications of similar results although part B is still in the early stages.
Disclaimer: This is my rough idea of what to expect next week and may contain errors, do your own research and know the risks.
Any thoughts why they released the RNS at 12PM?
Well the update is due next week, maybe they'll release the results before the conference. Until then, people are just going to be manipulating the SP.